Celine Rivera, MD
Internal Medicine · Ogden, UTNPI 1407052772
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.5% of the total across 672 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 10.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,071 and has fallen 57.2% since, to $1,313 in 2025. Among internal medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 672 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Biohaven Pharmaceuticals, Inc.$750
- Astellas Pharma US Inc$732
- Daiichi Sankyo Inc.$714
- AstraZeneca$703
- Pfizer$654
- plus $7K from 53 others
What the payments were for
- Consulting fees$7507%
- Food & beverage$10,74493%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$750
- INJECTAFER$250
- Mavyret$120
- LIBTAYO$106
How this compares
$11,494 in reported general payments places this provider in the 95th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 74 | $87,472 |
| OzempicSemaglutide | 73 | $86,763 |
| JardianceEmpagliflozin | 48 | $50,544 |
| EliquisApixaban | 44 | $41,786 |
| FarxigaDapagliflozin Propanediol | 21 | $29,973 |
| ProliaDenosumab | 12 | $20,884 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $16,926 |
| TradjentaLinagliptin | 15 | $16,419 |
| SunosiSolriamfetol Hcl | 11 | $9,306 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,168 |
| Levothyroxine Sodium | 292 | $3,602 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,816 |
| DilantinPhenytoin Sodium Extended | 13 | $2,652 |
| Omeprazole | 125 | $2,616 |
| Atorvastatin Calcium | 238 | $2,526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $620 | $87,47274 claims |
| Novo NordiskOzempic | $590 | $86,76373 claims |
| Boehringer IngelheimJardiance, Tradjenta | $502 | $66,96363 claims |
| PfizerEliquis, Dilantin | $654 | $44,43757 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $703 | $38,14134 claims |
| AmgenProlia | $1,254 | $20,88412 claims |
| GSKTrelegy Ellipta | $419 | $16,92617 claims |
| Axsome Therapeutics, Inc.Sunosi | $69 | $9,30611 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $43 | $3,602292 claims |
| AbbVieSynthroid | $518 | $1,11918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Ogden
- Justin MansfieldOgden$16K
- Matthew ReddOgden$8K
- Scott MoultonOgden$7K
- Donna MilavetzOgden$7K
- Robert MohrOgden$7K
- Kendell CoburnOgden$4K
- Willard DereSalt Lake City$4.7M
- Kenneth SchaecherWest Valley City$333K
- Steven CallSpringville$178K
- James ChamberlainSalt Lake City$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.